Ruiz-Fernandez de Cordoba et al., 2022 - Google Patents
Tumor ENPP1 (CD203a)/Haptoglobin axis exploits myeloid-derived suppressor cells to promote post-radiotherapy local recurrence in breast cancerRuiz-Fernandez de Cordoba et al., 2022
View HTML- Document ID
- 5845568180869151359
- Author
- Ruiz-Fernandez de Cordoba B
- Moreno H
- Valencia K
- Perurena N
- Ruedas P
- Walle T
- Pezonaga-Torres A
- Hinojosa J
- Guruceaga E
- Pineda-Lucena A
- Abengózar-Muela M
- Cochonneau D
- Zandueta C
- Martínez-Canarias S
- Teijeira
- Ajona D
- Ortiz-Espinosa S
- Morales X
- Ortiz de Solórzano C
- Santisteban M
- Ramos-García L
- Guembe L
- Strnad V
- Heymann D
- Hervás-Stubbs S
- Pío R
- Rodríguez-Ruiz M
- de Andrea C
- Vicent S
- Melero I
- Lecanda F
- Martínez-Monge R
- Publication year
- Publication venue
- Cancer discovery
External Links
Snippet
Locoregional failure (LRF) in patients with breast cancer post-surgery and post-irradiation is linked to a dismal prognosis. In a refined new model, we identified ectonucleotide pyrophosphatase/phosphodiesterase 1/CD203a (ENPP1) to be closely associated with LRF …
- 206010028980 Neoplasm 0 title abstract description 302
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ruiz-Fernandez de Cordoba et al. | Tumor ENPP1 (CD203a)/Haptoglobin axis exploits myeloid-derived suppressor cells to promote post-radiotherapy local recurrence in breast cancer | |
| Di Tacchio et al. | Tumor vessel normalization, immunostimulatory reprogramming, and improved survival in glioblastoma with combined inhibition of PD-1, angiopoietin-2, and VEGF | |
| Ames et al. | Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells | |
| Su et al. | Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma | |
| Aguilera et al. | Reprogramming the immunological microenvironment through radiation and targeting Axl | |
| Dammeijer et al. | Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy | |
| Li et al. | Epigenetic regulation of CXCL12 plays a critical role in mediating tumor progression and the immune response in osteosarcoma | |
| Mason et al. | Immunotherapy with a HER2-targeting listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma | |
| Traer et al. | FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia | |
| US20220127638A1 (en) | Non-hla matched humanized nsg mouse model with patient-derived xenograft | |
| Bald et al. | Immune cell–poor melanomas benefit from PD-1 blockade after targeted type I IFN activation | |
| Kobayashi et al. | LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution | |
| Muliaditan et al. | Repurposing tin mesoporphyrin as an immune checkpoint inhibitor shows therapeutic efficacy in preclinical models of cancer | |
| Gutiérrez-González et al. | Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma | |
| Body et al. | Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells | |
| Palladini et al. | HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response | |
| D'Amico et al. | C-met inhibition blocks bone metastasis development induced by renal cancer stem cells | |
| Boivin et al. | Anti-Ly6G binding and trafficking mediate positive neutrophil selection to unleash the anti-tumor efficacy of radiation therapy | |
| Vandereyken et al. | Dusp3 deletion in mice promotes experimental lung tumour metastasis in a macrophage dependent manner | |
| Mao et al. | Immunogenic hypofractionated radiotherapy sensitising head and neck squamous cell carcinoma to anti-PD-L1 therapy in MDSC-dependent manner | |
| Exposito et al. | PTEN loss confers resistance to anti–PD-1 therapy in non–small cell lung cancer by increasing tumor infiltration of regulatory T cells | |
| Zhang et al. | Heterogeneous cancer‐associated fibroblasts: a new perspective for understanding immunosuppression in pancreatic cancer | |
| Patterson et al. | The bone marrow immune microenvironment in CML: treatment responses, treatment-free remission, and therapeutic vulnerabilities | |
| Kruglov et al. | The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides | |
| Kleczko et al. | Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity |